Our Pricing

Buy Saxenda or Mounjaro Online UK - Fast Approval

Published on: June 03, 2026

When you buy Saxenda or Mounjaro online UK through Cured Pharmacy, you'll receive genuine UK-licensed weight loss injections with transparent upfront pricing, clinical assessment by UK prescribers, and discreet next-day delivery. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team have helped thousands of UK patients access prescription weight loss treatments safely and conveniently.

Mounjaro vs Saxenda: Understanding the Key Differences

Mounjaro (tirzepatide) and Saxenda (liraglutide) are both injectable GLP-1 receptor agonists licensed by the MHRA for weight management, but they differ significantly in mechanism, dosing frequency, and clinical outcomes. Mounjaro is the UK's first dual GIP/GLP-1 receptor agonist, activating two complementary metabolic pathways simultaneously, whilst Saxenda works through GLP-1 activation alone [1].

In head-to-head clinical comparisons, tirzepatide demonstrated superior weight loss outcomes. The SURPASS-3 trial showed patients achieved an average 22.5% body weight reduction over 72 weeks on the highest Mounjaro dose, compared to approximately 6% reduction with liraglutide in the SCALE trials [1][2]. Mounjaro requires just one weekly injection, whilst Saxenda is administered daily, which many patients find more convenient for long-term adherence.

At Cured Pharmacy, Mounjaro starts from £124.99 and Saxenda from £135.00, with final pricing determined by your prescribed dose following clinical assessment. Both treatments require a prescription from a UK-registered prescriber and are subject to clinical suitability assessment.

How Mounjaro (Tirzepatide) Works for Weight Loss

Tirzepatide's dual-action mechanism sets it apart from earlier weight loss medications. By activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, Mounjaro enhances insulin secretion, suppresses glucagon release, and significantly reduces appetite through central nervous system pathways [1].

Clinical trial data from the SURMOUNT-1 study demonstrated that patients without diabetes achieved up to 22.5% total body weight reduction over 72 weeks when combined with lifestyle modifications [3]. The medication also improved cardiovascular risk markers including blood pressure, lipid profiles, and inflammatory markers in most participants.

Mounjaro is administered as a once-weekly subcutaneous injection using the KwikPen device, starting at 2.5mg and titrating upward every four weeks to minimise gastrointestinal side effects. Your UK prescriber will determine the appropriate maintenance dose based on your response and tolerability, typically ranging from 5mg to 15mg weekly.

Who Can Use Mounjaro in the UK?

NICE guidance supports tirzepatide use for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities such as hypertension, type 2 diabetes, or obstructive sleep apnoea [4]. During your free online consultation at Cured Pharmacy, our UK prescribers assess your medical history, current medications, and weight loss goals to determine clinical suitability. Mounjaro is contraindicated in pregnancy, patients with personal or family history of medullary thyroid carcinoma, and those with multiple endocrine neoplasia syndrome type 2.

How Saxenda (Liraglutide) Works for Weight Management

Saxenda contains liraglutide 6mg/ml, a GLP-1 receptor agonist that mimics the natural incretin hormone released after eating. It works by slowing gastric emptying, reducing appetite through hypothalamic pathways, and improving glycaemic control in patients with insulin resistance [2].

The SCALE Obesity and Prediabetes trial demonstrated that patients achieved an average 8% body weight reduction over 56 weeks when combining liraglutide 3mg daily with reduced-calorie diet and increased physical activity [2]. Approximately 63% of participants lost at least 5% of their baseline weight, compared to 27% in the placebo group.

Saxenda requires daily subcutaneous injection, typically in the abdomen, thigh, or upper arm. Treatment begins at 0.6mg daily and increases weekly by 0.6mg increments until reaching the maintenance dose of 3mg daily. This gradual titration helps minimise common side effects such as nausea, which typically improves within the first few weeks of treatment.

Saxenda Dosing and Administration

Each Saxenda pen contains 18mg of liraglutide across multiple doses. Patients self-administer the injection once daily at any time, though maintaining consistency helps with routine adherence. The pen device features dose counters and audible clicks for accurate dosing. Your UK prescriber will provide comprehensive injection technique guidance, and our pharmacy team at Cured Pharmacy offers ongoing support throughout your treatment journey.

Comparing Effectiveness: Clinical Trial Data

Direct comparison of SURPASS and SCALE trial outcomes reveals meaningful differences in weight loss magnitude. In the SURPASS-3 study, participants on tirzepatide 15mg achieved mean weight reductions of 22.5% versus 6.2% with liraglutide over comparable timeframes [1][3]. These differences reflect tirzepatide's dual receptor activation mechanism.

Beyond weight loss, both medications demonstrated improvements in cardiometabolic health markers. Tirzepatide showed greater reductions in HbA1c, fasting glucose, and systolic blood pressure compared to liraglutide in patients with type 2 diabetes [1]. Both treatments reduced waist circumference and improved lipid profiles, though tirzepatide's effects were more pronounced across most measured parameters.

Treatment persistence matters significantly for long-term outcomes. The once-weekly Mounjaro injection showed higher adherence rates in real-world studies compared to daily liraglutide injections, though individual patient preferences vary [5]. Your UK prescriber will discuss which dosing schedule aligns better with your lifestyle and treatment goals during your clinical assessment.

Side Effects and Safety Considerations

Both Mounjaro and Saxenda share similar gastrointestinal side effect profiles, as expected with GLP-1 receptor agonists. The most commonly reported adverse effects include nausea (occurring in 30-40% of patients initially), vomiting, diarrhoea, constipation, and abdominal discomfort [1][2]. These effects are typically mild to moderate and diminish significantly after the first 4-8 weeks as your body adjusts.

More serious but rare risks include pancreatitis, gallbladder disease, and hypoglycaemia (particularly when combined with insulin or sulfonylureas). Both medications carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though human relevance remains unclear [4]. Your UK prescriber will screen for contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

At Cured Pharmacy, our clinical team monitors your progress through follow-up assessments and adjusts treatment as needed. We provide 24/7 access to pharmacist support for any concerns about side effects or medication administration. All adverse reactions should be reported to your prescriber and can also be reported via the MHRA Yellow Card scheme.

Managing Common Side Effects

To minimise gastrointestinal symptoms, eat smaller, more frequent meals, avoid high-fat foods, and stay well-hydrated throughout treatment. The gradual dose titration schedule for both medications helps your digestive system adapt. If nausea persists beyond the first month or becomes severe, contact your prescriber as dose adjustment may be appropriate. Never discontinue treatment abruptly without clinical guidance.

How to Buy Saxenda or Mounjaro Online UK at Cured Pharmacy

Purchasing prescription weight loss injections through Cured Pharmacy follows a straightforward, clinically governed process. Start by completing our free online consultation, which takes under 3 minutes and covers your medical history, current medications, weight loss goals, and any contraindications. Our UK-registered prescribers (regulated by the General Pharmaceutical Council) review every assessment individually.

If clinically appropriate, your prescriber will issue a prescription and our pharmacy team dispenses genuine UK-licensed medication from MHRA-approved suppliers. We offer discreet next-day delivery across the UK in plain, unbranded packaging. All prices are displayed upfront before consultation—Mounjaro from £124.99, Saxenda from £135.00—with no hidden fees or surprise charges at checkout.

As a GPhC-registered pharmacy (9012511), we operate under strict regulatory oversight. Superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets clinical safety standards and UK pharmacy law requirements. We never supply prescription-only medicines without valid clinical assessment, and we maintain full clinical records in accordance with UK healthcare regulations.

Ongoing Support and Repeat Prescriptions

Weight loss treatment requires ongoing monitoring and support. Our clinical team conducts regular follow-up assessments to evaluate your progress, adjust dosing if needed, and address any concerns. Repeat prescriptions are streamlined through your patient account, with reminders sent before your medication runs out. You can contact our pharmacy team on (+44) 116 4646009 during business hours or via our online messaging system for medication queries, injection technique support, or clinical advice.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
3. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes [TA924]. NICE. https://www.nice.org.uk/guidance/ta924 [accessed 13 August 2026]
5. Blonde, L., Pencek, R., & MacConell, L. (2015). Association Among Weight Change, Glycemic Control, and Markers of Cardiovascular Risk With Exenatide Once Weekly: A Pooled Analysis of Patients With Type 2 Diabetes. Cardiovascular Diabetology, 14, 12. https://doi.org/10.1186/s12933-015-0176-3 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to prescribed treatment combined with lifestyle modifications.